跳转至内容
Merck
CN

341607

PD 173074

≥97% (HPLC), FGF and VEGF receptor inhibitor, solid

别名:

FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074, 1- t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX, 1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C28H41N7O3
化学文摘社编号:
分子量:
523.67
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074, The FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 controls the biological activity of FGF/VEGF Receptor Tyrosine Kinase. Primarily used for Phosphorylation & Dephosphorylation applications.

SMILES string

N(CCCCNc1nc2nc(c(cc2cn1)c3cc(cc(c3)OC)OC)NC(=O)NC(C)(C)C)(CC)CC

InChI

1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)

InChI key

DXCUKNQANPLTEJ-UHFFFAOYSA-N

assay

≥97% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

yellow

solubility

DMSO: 100 mg/mL

shipped in

ambient

storage temp.

2-8°C

Quality Level

Disclaimer

Toxicity: Irritant (B)

General description

A cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC50 = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50<5 nM) and overexpressed VEGFR2 (IC50<200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.

Other Notes

Koziczak, M., et al. 2004. Oncogene23, 3501.
Trudel, S., et al. 2004. Blood103, 3521.
Skaper, S.D., et al. 2000. J. Neurochem.75, 1520.
Mohammadi, M., et al. 1998. EMBO J.17, 5896.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jharna R Das et al.
Disease models & mechanisms, 14(7) (2021-07-27)
People of African ancestry living with the human immunodeficiency virus-1 (HIV-1) are at risk of developing HIV-associated nephropathy (HIVAN). Children with HIVAN frequently show high plasma fibroblast growth factor-2 (FGF-2) levels; however, the role of circulating FGF-2 in the pathogenesis
Zhengtian Lyu et al.
Poultry science, 102(1), 102287-102287 (2022-11-29)
Fibroblast growth factor 23 (FGF23), a bone-derived hormone, is involved in the reabsorption of phosphate (P) and the production of vitamin D hormones in the kidney. However, whether and how FGF23 regulates chicken bone metabolism remains largely unknown. In the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持